图片: | |
---|---|
名称: | |
描述: | |
wangzhen_01 离线
duanfl8888 离线
HER2 CISH8482; 试剂盒
wangzhen_01 离线
wangzhen_01 离线
wangzhen_01 离线
wangzhen_01 离线
wangzhen_01 离线
wangzhen_01 离线
wangzhen_01 离线
wangzhen_01 离线
Her-2原位杂交图漂亮极了!Her-2 mRNA阳性定位的判断是否是只有定位于胞膜才算?有无胞浆阳性者?一提到这个,我就想起了乳腺癌中C-erbB-2的免疫组化的阳性定位问题。是否只有定位于胞膜才算阳性?如果胞膜和胞浆同时表达算吗?只有胞浆阳性呢?因为目前我们科室正在对多家试剂公司的C-erbB-2进行实验。某些国内知名试剂公司在其产品目录册说明上对其定位部位指明:胞浆或胞膜。以前我们也一直是已这种标志进行评判的,但后来问题来了。弄得我们很困惑。王版主,不知国外目前对此看法如何? |
wangzhen_01 离线
Wolff, A. C., M. E. Hammond, et al. (2007). "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer." J Clin Oncol 25(1): 118-45.
PURPOSE: To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker. METHODS: The American Society of Clinical Oncology and the College of American Pathologists convened an expert panel, which conducted a systematic review of the literature and developed recommendations for optimal HER2 testing performance. The guideline was reviewed by selected experts and approved by the board of directors for both organizations. RESULTS: Approximately 20% of current HER2 testing may be inaccurate. When carefully validated testing is performed, available data do not clearly demonstrate the superiority of either immunohistochemistry (IHC) or in situ hybridization (ISH) as a predictor of benefit from anti-HER2 therapy. RECOMMENDATIONS: The panel recommends that HER2 status should be determined for all invasive breast cancer. A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed. Elements to reliably reduce assay variation (for example, specimen handling, assay exclusion, and reporting criteria) are specified. An algorithm defining positive, equivocal, and negative values for both HER2 protein expression and gene amplification is recommended: a positive HER2 result is IHC staining of 3+ (uniform, intense membrane staining of > 30% of invasive tumor cells), a fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus or a FISH ratio (HER2 gene signals to chromosome 17 signals) of more than 2.2; a negative result is an IHC staining of 0 or 1+, a FISH result of less than 4.0 HER2 gene copies per nucleus, or FISH ratio of less than 1.8. Equivocal results require additional action for final determination. It is recommended that to perform HER2 testing, laboratories show 95% concordance with another validated test for positive and negative assay values. The panel strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored with the use of stringent laboratory accreditation standards, proficiency testing, and competency assessment. The panel recommends that HER2 testing be done in a CAP-accredited laboratory or in a laboratory that meets the accreditation and proficiency testing requirements set out by this document.
我会抽时间把问题说明一下的,谢谢捧场,呵呵。